drugset
drugset / Trial / NCT02083640

Relative Bioavailability For Palbociclib Formulations

NCT02083640 ↗

Phase 1 Completed 30 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This study is to assess the relative bioavailability of palbociclib hard gelatin capsule formulation (API 41 micrometer and dissolution Level 1) and palbociclib hard gelatin capsule formulation (API 16 micrometer and dissolution Level 2) compared to the palbociclib hard gelatin capsule formulation (API 16 micrometer and dissolution Level 1) after single 125 mg oral doses under fed conditions in healthy volunteers.

Timeline

Start
2014-03
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Palbociclib Small molecule 125 mg Oral

Indications

No indication recorded.